BioLineRx Ltd.
BLRXNASDAQHealthcare● Active
$3.25
+$0.02(+0.62%)
Market Cap$14141910
P/E Ratio—
52W High$6.59
52W Low$2.15
BioLineRx Ltd. (BLRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BLRX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 27, 2026EPS Actual
-$0.36
Est. -$1.04 · +65.4%
Revenue
$0.00B
Est. $0.00B · +39.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 27, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 3-Quarter EPS Beat Streak
BLRX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.15 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 27, 2026 | -$1.04 | -$0.36 | +65.4% | $0.00B | $0.00B | +39.1% |
| ▲ Q1 FY2026 | Mar 23, 2026 | -$0.39 | -$0.27 | +29.9% | $0.00B | $0.00B | -62.3% |
| ▲ Q4 FY2025 | Nov 24, 2025 | -$0.41 | -$0.22 | +46.3% | $0.00B | $0.00B | -36.3% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.35 | -$1.00 | -185.7% | $0.00B | $0.00B | -60.9% |
| ▲ Q2 FY2025 | May 27, 2025 | -$0.84 | $1.39 | +265.5% | $0.00B | $0.00B | -86.0% |
| ▲ Q1 FY2025 | Mar 25, 2025 | -$4.20 | $6.00 | +242.9% | $0.01B | $0.01B | +52.2% |
| ▼ Q4 FY2024 | Nov 25, 2024 | -$0.05 | -$2.80 | -5500.0% | $0.00B | $0.01B | -5.5% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.15
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 27, 2026Beat
EPS Actual
-$0.36
EPS Est.
-$1.04
EPS Surpr.
+65.4%
Revenue
$0.00B
Q1 FY2026
Mar 23, 2026Beat
EPS Actual
-$0.27
EPS Est.
-$0.39
EPS Surpr.
+29.9%
Revenue
$0.00B
Q4 FY2025
Nov 24, 2025Beat
EPS Actual
-$0.22
EPS Est.
-$0.41
EPS Surpr.
+46.3%
Revenue
$0.00B
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$1.00
EPS Est.
-$0.35
EPS Surpr.
-185.7%
Revenue
$0.00B
Q2 FY2025
May 27, 2025Beat
EPS Actual
$1.39
EPS Est.
-$0.84
EPS Surpr.
+265.5%
Revenue
$0.00B
Q1 FY2025
Mar 25, 2025Beat
EPS Actual
$6.00
EPS Est.
-$4.20
EPS Surpr.
+242.9%
Revenue
$0.01B
Q4 FY2024
Nov 25, 2024Miss
EPS Actual
-$2.80
EPS Est.
-$0.05
EPS Surpr.
-5500.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.17 | $-0.16 | $-0.15 | 1 |
| Q3 FY2027 | $-0.18 | $-0.17 | $-0.16 | 1 |
| Q2 FY2027 | $-0.17 | $-0.16 | $-0.15 | 1 |
| Q1 FY2027 | $-0.14 | $-0.13 | $-0.12 | 1 |
| Q4 FY2026 | $-0.10 | $-0.09 | $-0.08 | 1 |
| Q3 FY2026 | $-0.10 | $-0.09 | $-0.08 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 27, 2026 | +65.4% | $3.16 | $3.37 | +6.65% |
| ▲ Q1 FY2026 | Mar 23, 2026 | +29.9% | $2.65 | $2.32 | -12.45% |
| ▲ Q4 FY2025 | Nov 24, 2025 | +46.3% | $3.25 | $3.50 | +7.69% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -185.7% | $3.94 | $3.77 | -4.31% |
| ▲ Q2 FY2025 | May 27, 2025 | +265.5% | $3.66 | $3.68 | +0.55% |
| ▲ Q1 FY2025 | Mar 25, 2025 | +242.9% | $3.42 | $3.34 | -2.34% |
| ▼ Q4 FY2024 | Nov 25, 2024 | -5500.0% | $11.12 | $10.87 | -2.25% |
| ▲ Q3 FY2024 | Aug 15, 2024 | +385.7% | $31.00 | $27.13 | -12.48% |
Q2 FY2026+6.65%
Report Date
May 27, 2026
EPS Beat/Miss
+65.4%
Price Before
$3.16
Price After
$3.37
Q1 FY2026-12.45%
Report Date
Mar 23, 2026
EPS Beat/Miss
+29.9%
Price Before
$2.65
Price After
$2.32
Q4 FY2025+7.69%
Report Date
Nov 24, 2025
EPS Beat/Miss
+46.3%
Price Before
$3.25
Price After
$3.50
Q3 FY2025-4.31%
Report Date
Aug 14, 2025
EPS Beat/Miss
-185.7%
Price Before
$3.94
Price After
$3.77
Q2 FY2025+0.55%
Report Date
May 27, 2025
EPS Beat/Miss
+265.5%
Price Before
$3.66
Price After
$3.68
Q1 FY2025-2.34%
Report Date
Mar 25, 2025
EPS Beat/Miss
+242.9%
Price Before
$3.42
Price After
$3.34
Q4 FY2024-2.25%
Report Date
Nov 25, 2024
EPS Beat/Miss
-5500.0%
Price Before
$11.12
Price After
$10.87
Q3 FY2024-12.48%
Report Date
Aug 15, 2024
EPS Beat/Miss
+385.7%
Price Before
$31.00
Price After
$27.13
Avg Beat Reaction-2.06%
Avg Miss Reaction-3.28%
Beat Rate6 / 8 quarters
Largest Move-12.48% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BLRX ends December
BioLineRx Ltd. (BLRX) most recently reported earnings on May 27, 2026 for Q2 FY2026, posting EPS of $-0.36 — beating the analyst consensus of $-1.04 by +65.4%. BLRX has beaten EPS estimates for 3 consecutive quarters. The next BLRX earnings date is expected around September 1, 2026.
Each quarter, investors track BLRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BLRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BLRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BLRX earnings · 5 questionsBioLineRx Ltd.'s next earnings report is expected around September 1, 2026. BLRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BLRX historically reports after market close (AMC).
BLRX earnings datewhen is BLRX earningsBLRX next earnings datewhen does BLRX report earningsBLRX earnings calendar
▸ Source: FMP · BioLineRx Ltd. SEC filings · US GAAP · BioLineRx Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026